Group 1 - Kairos Pharma's stock (KAPA) is experiencing a significant increase, trading at $1.12 with a volume of 221 million shares compared to an average of 874.3K [1][7] - The company released positive interim safety results from its Phase 2 clinical trial of ENV-105 in patients with metastatic castration-resistant prostate cancer, indicating it was well tolerated with no dose-limiting toxicities or unexpected adverse events reported [2][3] - The Phase 2 trial aims to enroll 100 patients to evaluate the safety, tolerability, and early efficacy of ENV-105, with interim efficacy data expected in September 2025 [3] Group 2 - The stock price of Kairos Pharma has increased by 57.64%, reaching $1.08 at the time of publication [7] - The treatment-related side effects of ENV-105 were manageable with standard supportive care, and no Grade 3 or 4 toxicities were observed [2]
Why Is Kairos Pharma Stock Surging On Tuesday?